Celularity Inc (CELU) stock

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30

$0.68−0.07 (-8.81%)

Close on Nov 12, 2026Market cap $22.22MP/E –Yield –

Earnings

Celularity's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

–

Not yet scheduled

Revenue, Q3 FY2022

$4.14M

-61.1% on a year earlier

EPS, Q3 FY2022

$0.03

$0.40 a year earlier

Latest guidance

Issued

Nov 7, 2024 · 1 item

Quarterly results

Revenue and earnings per share from each of Celularity's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q1 FY2025ended Mar 31, 2025	May 9, 2025during market hours	–	–	–	Release
Q3 FY2024ended Sep 30, 2024	Nov 7, 2024before the open	–	–	–	Release
Q1 FY2024ended Mar 31, 2024	May 21, 2024before the open	–	–	–	Release
Q4 FY2023ended Dec 31, 2023	Jan 9, 2024during market hours	–	–	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 10, 2022during market hours	$4.14M	-61.1%	$0.03	Release
Q2 FY2022ended Jun 30, 2022	Aug 10, 2022during market hours	–	–	–	Release
Q1 FY2022ended Mar 31, 2022	May 16, 2022during market hours	$5.90M	–	-$0.48	Release
Q4 FY2021ended Dec 31, 2021	Mar 31, 2022during market hours	$4.90M	–	-$0.03	Release
Q3 FY2021ended Sep 30, 2021	Nov 12, 2021during market hours	$10.62M	–	$0.40	Release
Q2 FY2021ended Jun 30, 2021	Aug 16, 2021during market hours	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Celularity's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
net sales of its biomaterial products and biobanking businesses	Q4 FY2023	$11.40M – $12.10M	–	New	Jan 9, 2024
net sales percentage growth	Q4 FY2023	+176.1% – +193%	–	New	Jan 9, 2024
net sales of its biomaterial products and biobanking businesses	FY2023	$22.06M – $22.76M	–	New	Jan 9, 2024
net sales percentage growth	FY2023	+22.7% – +26.6%	–	New	Jan 9, 2024
combined Net Sales of our advanced biomaterial product and biobanking businesses	FY2024	$50.00M – $56.00M	–	New	Oct 25, 2024
expected net sales guidance	FY2024	$54.00M – $60.00M	–	New	Nov 7, 2024

Guidance history

Every forecast Celularity put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Nov 7, 2024	expected net sales guidance	FY2024	$54.00M – $60.00M	New
Oct 25, 2024	combined Net Sales of our advanced biomaterial product and biobanking businesses	FY2024	$50.00M – $56.00M	New
Jan 9, 2024	net sales percentage growth	Q4 FY2023	+176.1% – +193%	New
Jan 9, 2024	net sales percentage growth	FY2023	+22.7% – +26.6%	New
Jan 9, 2024	net sales of its biomaterial products and biobanking businesses	Q4 FY2023	$11.40M – $12.10M	New
Jan 9, 2024	net sales of its biomaterial products and biobanking businesses	FY2023	$22.06M – $22.76M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.